A Study of Neuroimaging to Assess the Underlying Disease Progression in Progressive Apraxia of Speech


About this study

The purpose of this study is to utilize neuroimaging to assess the neurobiological mechanisms underlying disease progression in progressive apraxia of speech.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Progressive Apraxia of Speech Inclusion and Exclusion Criteria:

  • All enrolled subjects must be over the age of 18.
  • Must have an informant who will be able to provide independent evaluation of functioning.
  • Must speak English as their primary language.
  • Bilingual subjects and minorities whose primary language is English will be recruited.
  • To be included in the study, subjects must have a chief complaint of progressive impairment of speech or language with evidence of apraxia of speech or agrammatic aphasia in which verbal and/or written output will show evidence of agrammatism.
  • Difficulties with verbal comprehension, reading comprehension, writing and naming also may be present.
  • In subjects with anomia the target words should be recognized when provided on the majority of items.
  • Dysarthria may be present but must be rated as no more than mild.

Inclusion and Exclusion Criteria for the PAOS task fMRI:

  • The task-based fMRI will require subjects to speak into the scanner and understand simple instructions.
    • Therefore, to be included in the task-based fMRI component subjects must be able to demonstrate good understanding of the task during training.

Healthy Control Inclusion and Exclusion Criteria:

  • Healthy controls recruited into this study must be independently functioning and not have any active neurologic or psychiatric conditions and have no cognitive complaints. We will exclude subjects that have past or persistent childhood speech or language disorders and/or learning disabilities.

Exclusion Criteria:

  • Women that are pregnant or post-partum and breast-feeding will be excluded.
  • All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan.
  • Subjects will be excluded from the study if MRI is contraindicated as a result of MR unsafe implanted metallic devices, if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g., structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g., chemotherapy).
  • Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes, brain surgery, tumors, or developmental syndromes will be excluded.
  • Subjects that are mute or meet criteria for another neurodegenerative disease, including Alzheimer’s disease, Lewy body disease, or the semantic or logopenic variants of primary progressive aphasia, will be excluded.
  • Subjects will also be excluded if they do not have an informant, or do not consent to research.

Additional General Exclusion Criteria for 7T task fMRI

  • All subjects and controls will be excluded from undergoing the task fMRI san if they have active implant devices (such as cardiac defibrillators/pacemakers, heart monitors, cohlear implants) or if they have abandoned cardiac pacer wires, orthopedic implants that are near the spinal cord or temperature sensitive organs, metallic implants near the orbits, external devices that cannot be removed from the body (such as medicinal patches, piercings, jewelry, clothing or hair accessories), temporary tattoos or those obtained prior to 1995, colored contact lens, any ‘undefined’ metallic implants of foreign bodies inside the patient, or if subjects are pregnant.





Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Keith Josephs, M.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Sarah Boland CCRP

(507) 284-3863


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer